| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| Targets |
Ras
|
|---|---|
| References | |
| Additional Infomation |
Antineoplaston A10 has been used in trials studying the treatment of Sarcoma, Lymphoma, Lung Cancer, Liver Cancer, and Kidney Cancer, among others.
Antineoplaston A10 is a piperidinedione antineoplaston with potential antineoplastic activity. Antineoplaston A10 was originally isolated from human urine but is now synthetically derived. This agent intercalates into DNA, resulting in cell cycle arrest in G1 phase, reduction of mitosis, and decreased protein synthesis. Antineoplaston A10 may also inhibit ras-oncogene expression and activate tumor suppressor gene p53, leading to cell differentiation and apoptosis. (NCI04) |
| Molecular Formula |
C13H14N2O3
|
|---|---|
| Molecular Weight |
246.27
|
| Exact Mass |
246.1
|
| Elemental Analysis |
C, 68.74; H, 6.29; O, 24.97
|
| CAS # |
91531-30-5
|
| Related CAS # |
(Rac)-Antineoplaston A10;77658-84-5
|
| PubChem CID |
56260
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.266
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
18
|
| Complexity |
348
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N([C@H]1CCC(=O)NC1=O)C(=O)CC1C=CC=CC=1
|
| InChi Key |
OQGRFQCUGLKSAV-JTQLQIEISA-N
|
| InChi Code |
InChI=1S/C13H14N2O3/c16-11-7-6-10(13(18)15-11)14-12(17)8-9-4-2-1-3-5-9/h1-5,10H,6-8H2,(H,14,17)(H,15,16,18)/t10-/m0/s1
|
| Chemical Name |
N-[(3S)-2,6-dioxopiperidin-3-yl]-2-phenylacetamide
|
| Synonyms |
ANP-A-10; ANPA-10; ANP A 10; ANPA 10
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 49~250 mg/mL (199.0~1015.2 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0606 mL | 20.3029 mL | 40.6058 mL | |
| 5 mM | 0.8121 mL | 4.0606 mL | 8.1212 mL | |
| 10 mM | 0.4061 mL | 2.0303 mL | 4.0606 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05498077 | Active Recruiting |
Procedure: Body scan meditation | Chronic Pain | Therapeutic Neuroscience Research Group |
May 1, 2021 | Not Applicable |
| NCT02887040 | Not yet recruiting | Drug: Atengenal Drug: Astugenal |
Brain Stem Glioma | Burzynski Research Institute | June 1, 2024 | Phase 3 |
| NCT05583955 | Active Recruiting |
Drug: NOE-105 Drug: Placebo |
Childhood-Onset Fluency Disorder |
Noema Pharma AG | July 25, 2022 | Phase 2 |
| NCT05533242 | Recruiting | Drug: Lu-177 labeled 6A10- Fab-fragments |
Glioblastom WHO Grade 4 | University Hospital Muenster | June 2023 | Phase 1 |
| NCT02864888 | Not yet recruiting | Radiation: Radiation Drug: Atengenal |
Brain Stem Glioma | Burzynski Research Institute | June 2024 | Phase 3 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA